3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Follicular
7
Lymphoma
7
Lymphoma, Non-Hodgkin
6
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Waldenstrom Macroglobulinemia
2
Lymphoma, B-Cell
2
Burkitt Lymphoma
2
Recurrence
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Dendritic Cell Sarcoma, Interdigitating
1
Interventions
Cyclophosphamide
4
Rituximab
3
cobomarsen
2
Vincristine
2
Prednisone
2
Etoposide
2
Doxorubicin
2
thymoglobulin
1
ponatinib
1
ibritumomab tiuxetan
1
fludarabine phosphate
1
fludarabine
1
Vorinostat
1
Tacrolimus
1
Mycophenolic Acid
1
Melphalan
1
Imatinib Mesylate
1
Ifosfamide
1
Cytarabine
1
Carmustine
1
Carboplatin
1
Busulfan
1
Brentuximab Vedotin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Immune System Diseases
×
ibritumomab tiuxetan
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts